SMAD2 and acute myeloid leukemia: Recently, researchers have found that FAT1 can reduce autophagy levels and proliferation activity in AML cells by downregulating ATG4B expression through the inhibition of TGFβ-Smad2/3 signaling, suggesting that FAT1 might be a new target for developing AML-targeted therapies (21).